A Phase 1 interventional study of SLIT™ Amikacin and Placebo in Cystic Fibrosis, sponsored by Insmed Incorporated. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.
Sponsored by Insmed Incorporated · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to evaluate the safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.
1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.
This study's enrollment of 18 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Browse Cystic Fibrosis studies →Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of SLIT™ amikacin at Dose 1 or matching placebo by inhalation on Day 0.
Drug: SLIT™ Amikacin · Drug: Placebo
Participants will receive a single dose of SLIT™ amikacin at Dose 2 or matching placebo by inhalation on Day 0 upon initiation of Cohort 2.
Drug: SLIT™ Amikacin · Drug: Placebo
Participants will receive a single dose of SLIT™ amikacin at Dose 3 or matching placebo by inhalation on Day 0 upon initiation of Cohort 3.
Drug: SLIT™ Amikacin · Drug: Placebo
Amikacin administered via the Pari LC STAR™ nebulizer.
Also known as: TR02
Nebulized saline.
Number of Participants who Experience a Treatment Emergent Adverse Event (TEAE)
Safety and tolerability of three active doses of nebulized amikacin in a SLIT™ formulation.
Time frame: Up to Day 28
Area Under the Concentration-time Curve (AUC) of SLIT™ Amikacin in Serum
Time frame: Pre-dose and at multiple time points post-dose up to Day 3
Percent Dose of SLIT™ Amikacin in Urine
Time frame: At multiple time points post-dose up to Day 3
AUC of SLIT™ Amikacin in Sputum
Time frame: Pre-dose and at multiple time points post-dose on Days 1, 2, 3, 8, 14, and 28
Change From Baseline in Sputum Density of Pseudomonas Aeruginosa
Time frame: Baseline up to Day 28
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2004 to primary completion in Feb 2005, 8 months.
Of 39 industry-sponsored phase 1 interventional studies under Cystic Fibrosis, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 8 months is close to that.
Counting every sponsor, half of 62 studies reached it within 10 months; a quarter within 5 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.